Bruce Brockstein to Antibodies, Monoclonal
This is a "connection" page, showing publications Bruce Brockstein has written about Antibodies, Monoclonal.
Connection Strength
0.280
-
Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. Lancet Oncol. 2013 Apr; 14(4):371-82.
Score: 0.072
-
A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancer. J Natl Compr Canc Netw. 2012 Nov 01; 10(11):1391-8.
Score: 0.070
-
Management of recurrent head and neck cancer: recent progress and future directions. Drugs. 2011 Aug 20; 71(12):1551-9.
Score: 0.065
-
The role of inhibitors of the epidermal growth factor in management of head and neck cancer. J Natl Compr Canc Netw. 2008 Aug; 6(7):696-706.
Score: 0.052
-
Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model. Ann Oncol. 2015 07; 26(7):1459-64.
Score: 0.021